KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Non Operating Income (2016 - 2025)

Historic Non Operating Income for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $912000.0.

  • TherapeuticsMD's Non Operating Income rose 6084.66% to $912000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 3480.87%. This contributed to the annual value of $2.4 million for FY2024, which is 20947.5% up from last year.
  • Per TherapeuticsMD's latest filing, its Non Operating Income stood at $912000.0 for Q3 2025, which was up 6084.66% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Non Operating Income ranged from a high of $25.3 million in Q4 2021 and a low of -$22.8 million during Q1 2022
  • Its 5-year average for Non Operating Income is -$919947.4, with a median of $58000.0 in 2023.
  • Data for TherapeuticsMD's Non Operating Income shows a peak YoY increase of 289827.59% (in 2024) and a maximum YoY decrease of 238518.52% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows TherapeuticsMD's Non Operating Income stood at $25.3 million in 2021, then tumbled by 99.96% to $11000.0 in 2022, then skyrocketed by 145.45% to $27000.0 in 2023, then crashed by 2385.19% to -$617000.0 in 2024, then soared by 247.81% to $912000.0 in 2025.
  • Its last three reported values are $912000.0 in Q3 2025, $1.2 million for Q2 2025, and $203000.0 during Q1 2025.